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INTRODUCTION
The incidence of squamous cell carcinoma of the anus (SCCA) has increased globally over the last 3 decades 1 , most markedly in high income countries, where (world) standardised incidence rates range from 0.4 to 1.8 per 100,000. Historically, primary treatment of SCCA was by radical surgical resection, but a paradigm shift occurred in the 1970s and 1980s when small studies demonstrated high rates of local control with primary radiotherapy, with or without chemotherapy, 2, 3 and an opportunity for anal sphincter preservation. Subsequently, six phase III randomised trials (2877 patients) in Europe and the USA established the effectiveness of chemoradiotherapy as primary treatment. [4] [5] [6] [7] [8] [9] Over this period, survival progressively improved; currently 5-year overall survival rates approach 75%. 10 However, this success has come at the cost of considerable treatment-related acute and long-term toxicity.
Across the above six trials, there is considerable variation in trial outcome reporting limiting between-study comparisons and hindering evidence synthesis. 11 Furthermore, outcomes in these trials were primarily related to survival and disease activity; no trial comprehensively addressed long-term side effects or quality of life (QoL). Both of these issues can be addressed by the development of a core outcome set (COS) "an agreed, standardised set of outcomes to be measured and reported, as a minimum, in all trials in a particular health area"
12
. COS have been endorsed as a means to reduce outcome heterogeneity, and to increase the relevance of research through involvement of key stakeholders in COS development 13 . This paper describes the development of a COS for trials of chemoradiotherapy interventions for SCCA.
METHODS

Scope
The scope of the core outcome set to be developed has been defined according to the criteria recommended by COMET 14 .
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Health condition: Non-recurrent, non-metastatic squamous cell carcinoma of the anus/ anal canal (SCCA)
Population: Adults >18 years of age
Types of Interventions: Primary treatment with chemoradiotherapy
Setting: Later phase trials that will inform clinical decision making
Study overview
The COS was developed in three phases, inclusive of patients and health professionals at each stage: (1) A long-list of outcomes was generated through systematic review 15 and semistructured patient interviews; (2) . The outcome long-list was used to populate the 2-phase Delphi process; (3) The results of the Delphi survey were reviewed at a face-to-face consensus meeting and a final COS determined.
Phase 1: Information Gathering
Search strategy and selection criteria
Full details of the systematic review, including search strategy, databases and selection criteria have been published elsewhere. 15 Outcomes and accompanying definitions were extracted verbatim from included studies and categorised into domains.
Semi-structured interviews
Outcomes of importance to patients were identified through semi-structured interviews. This approach uses open questions to facilitate a patient-led discussion, guided by additional prompts from a pre-prepared topic guide to ensure key areas are covered. Patient participants for the semi-structured interviews were identified and recruited from the Christie NHS Foundation Trust (Manchester, United Kingdom) anal cancer database and through the Macmillan anal cancer forum, 16 following a purposive sampling matrix defined a priori.
Eligibility criteria and the sampling matrix are available in the study protocol. 17 Written informed consent was obtained before interviews. Outcomes were identified both indirectly through
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Long-list generation
Outcomes from the systematic review and patient interviews were combined. The long-list of outcomes, accompanied by relevant quotes from the patient interviews, was discussed by the CORMAC Study Advisory Group (SAG, described below) (September 2017 
Phase 2: Delphi Survey
The Delphi survey was run using the online DelphiManager platform. 18 Participants were recruited from the two key stakeholder groups: patients and health care professionals (HCPs).
Clinical researchers involved in clinical trials formed a subgroup within the HCP stakeholder group. Patient were recruited from four UK treatment centres, via social media (Twitter) and patient advocacy groups (Supplementary file S1). Patients were asked to confirm that they had received or were receiving treatment with chemoradiotherapy for SCCA in a declaration when registering to take part in the Delphi. HCPs were recruited by direct e-mail to principal investigators in the PLATO (PersonaLising Anal cancer radioTherapy dOse) trial 19 and via UK and international professional organisations (Supplementary file S1). Eligibility criteria are detailed in the study protocol. The Delphi process was conducted over 2 rounds (termed R1 and R2). In each round, participants were asked to rate the importance of including each CORMAC Core Outcome Set v1.8 04/07/2018 6 outcome in the COS on a 1-9 scale described as: Limited importance (1-3); important but not critical (4-6); and critically important (7) (8) (9) . Participants could suggest additional outcomes at the end of R1which were reviewed by the core team (RF, CS, AGR and PRW); any outcome not already represented was added to R2. No outcomes were dropped between rounds. In R2, participants were shown a histogram of the R1 scores for each outcome together with their own R1 score, before being asked to reflect on the information presented and score each outcome again.
The percentage of participants scoring each of 1-9 was calculated from the R2 scores for each outcome. Consensus criteria were defined a priori: 12 outcomes scored as 'critically important' (7-9) by ≥70% of patients and ≥70% of HCPs, and 'limited importance' (1-3) by ≤15% of patients and ≤15% of HCPs were defined as 'consensus in' and included in the provisional COS. Outcomes scored 1-3 by ≥70% and 7-9 by ≤15% of both stakeholder groups were defined as 'consensus out' and were excluded. Outcomes not fulfilling criteria for consensus in or out were defined as 'no consensus'.
Phase 3: Consensus Meeting
The results of the Delphi survey were presented at a face-to-face consensus meeting.
Participants were eligible to attend if they had completed both rounds of the Delphi survey.
Participants were sampled purposively to promote balanced representation of patients and
HCPs of differing disciplines. International participation was capped for budgetary reasons.
Prior to the meeting, all participants were sent a summary of their own Delphi R2 scores. The meeting was chaired by an independent, non-clinical researcher with expertise in COS development methodology (SB), and not a member of the SAG.
Outcomes identified in R2 of the Delphi as 'consensus in' were presented first and participants asked if there were any fundamental reasons why these should not be included in the COS.
Outcomes deemed 'consensus out' were reviewed and participants asked if there were any fundamental reasons why these should be included in the COS. All 'no consensus' outcomes were discussed and voted on with outcomes where one stakeholder group had scored ≥70%
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CORMAC Core Outcome Set v1.8 04/07/2018 7 7-9 considered first. Remaining 'no consensus' outcomes were reviewed together, with individual outcomes being discussed and voted on only if proposed as being important by a meeting participant. Contrasting views were actively sought and the chair ensured all participants had equal opportunity to contribute before voting commenced. Voting was conducted anonymously using TurningPoint© software and handsets (Turning Technologies LLC, Youngstown, USA). Voting followed the same format as in the Delphi, with results displayed to participants immediately for each outcome. Outcomes meeting the criteria for 'consensus in' were included in the COS; all other items were dropped. At the end of the meeting, the final COS was presented to participants and ratified.
Other analyses
We assessed for attrition bias between Delphi R1 and R2, comparing the distribution of mean R1 scores for participants did and did not complete R2
12
.
We assessed for consensus meeting participation bias by comparing the distribution of mean R2 scores for participants who did and did not participate in the consensus meeting. To assess satisfaction with the process and outcome of the consensus meeting, we collected questionnaire feedback from participants,
(Supplementary file S2).
Ethics and registration
Our findings are reported in line with the Core Outcome Set-Standards for Reporting (COS-STAR) reporting guidance. 20 This project was prospectively registered with the COMET initiative (Core Outcome Measures in Effectiveness Trials). 21 The study protocol and composition of the SAG have been published elsewhere. 17 The study was approved by the 
RESULTS
An overview of the CORMAC COS development process and of the final COS is shown in figure 1.
Phase I: Information Gathering
The systematic review has been described in detail elsewhere [16] . In brief,1243 outcomes were identified from 101 studies, consolidated into 92 standardised outcome terms. Interviews with 19 patients identified 61 57 outcomes, including eight not identified from the literature (skin pain, skin itch, sleep disturbance, bone/joint pain, fertility, menopause, ejaculatory function and orgasmic function). The 100 standardised outcome terms were categorised into five domains (survival; disease activity; life impact; delivery of care; and toxicity). which can be directly mapped to the outcome domain taxonomy recommended by COMET 22 . After discussion by the SAG, 73 standardised outcome terms were taken forward into the Delphi process; one outcome was expanded into two and 28 were removed. Full details of the outcomes excluded along with the reasons are available in supplementary file S3.
Phase 2: Delphi Process
One hundred and forty-nine participants from 11 countries (patients 55; HCPs 94) completed both rounds of the Delphi process. Participant characteristics are shown in Table 1 . Thirty additional outcomes were proposed during R1, of which five were added into R2, and two outcome descriptions were revised (supplementary file S4). The full list of Delphi question items is available in supplementary file S5.
The R2 results are summarised in Table 2 . Fourteen outcomes met the criteria for 'consensus in'. No outcomes met the original criteria for 'consensus out' so it was agreed by the SAG to redefine the criteria for 'consensus out' to a majority rule; outcomes were classed as 'consensus out' if ≤50% of participants in both stakeholder groups scored the item as critically
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and R2 scores individual outcome are shown in supplementary file S6 and S7.
The attrition rate from R1 to R2 was 18% (14% HCPs; 25% patients). Comparison of mean R1 scores for participants who did and did not complete both rounds suggested that those who did not complete R2 may have been more likely to score all outcomes more highly than those continuing to R2 (Figure 2A ).
Phase 3: Consensus Meeting
Twenty-three HCPs and 13 patients participated in the consensus meeting (supplementary file S8). Comparison of the mean R2 scores of participants attending to those not attending the consensus meeting shows no evidence of any participation bias ( Figure 2B ). During analysis of the consensus meeting voting results, we noted one HCP had erroneously self-allocated to the patient group. If they had selected the correct stakeholder group, it is
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CORMAC Core Outcome Set v1.8 04/07/2018 10 possible that one outcome (sexual function) may not have reached 70% 7-9 in the HCP group and would therefore not have been included in the COS. Since only one out of the 14 participants in the self-allocated patient group scored this outcome less than seven, the probability of correct self-allocation changing the results is only 7% (1/14) . Additionally, the final core outcome set was reviewed and agreed by all participants at the close of the consensus meeting. We therefore recommend that the original results stand.
The final COS (Figure 1 ) includes 19 outcomes across four domains (6 disease activity; 5 survival; 5 toxicity; 3 life impact). These were: treatment response, local failure, regional failure, distant failure, disease progression, salvage surgery, overall survival, cancer-specific survival, disease-free survival, metastasis-free survival, progression-free survival, anal incontinence, faecal urgency, pelvic fistula, stoma, skin loss, physical function, sexual function, and health-related QoL.
The feedback questionnaire was completed by 74% (17/23) HCPs and all patients. All patient participants and 16/17 HCPs were comfortable communicating their views during the meeting (one HCP was ambivalent). All patients and 15/17 HCPs agreed that the meeting produced a fair result. The remaining HCPs deferred judgement until the final report was produced.
Participants from both stakeholder groups commended the meeting for facilitating discussion between HCPs and patients.
DISCUSSION
Main findings
Our study is the first international combined HCP-patient consensus on outcomes for trials in SCCA. All the included outcomes were all identified as critically important by over 70% of both patients and HCPs, using consensus methods which ensured representation of these groups on an equal footing. We recommend that all future trials evaluating chemo-radiotherapy for SCCA utilise the COMRAC COS as a framework for outcome selection.
In context with other literature
We have not identified any other published COS for anal cancer. Glynne-Jones et al 23 previously identified the need for consensus on outcome definitions in anal cancer trials , but made recommendations based on the view of the authors without direct involvement of patients or the wider community of HCPs. In contrast, both patients and a broad range of
HCPs have been involved in each stage of the development of this COS.
In our initial systematic review linked to this consensus, 15 we identified more than ten different survival or survival composite outcome terms in use, all with varying definitions. With the exception of overall survival, no survival outcome was reported in every randomised trial, and none has a single agreed definition. This heterogeneity reflects the lack of consensus (until now) on which survival endpoints to capture other than overall survival.
There were some unexpected inclusions and exclusions in the final COS. Colostomy-free survival, which has been commonly used in trials in this field, was not selected as a c ore outcome, but colostomy was. This illustrates the pitfalls of creating composite outcomes; even when the events used to create a composite outcome are of interest, relevance of the composite cannot be assumed. The difficulties of defining progression-free survival (PFS) and its validity as marker for improved survival or QOL have been widely discussed, 11, 15, [24] [25] [26] however PFS is included in the CORMAC COS, indicating that it holds relevance to both patients and HCPs. In the next phase of the project, we will work to agree standardised definitions for the included outcomes.
The new EORTC QOL module, ANL-27, 27 is an anal cancer-specific patient reported outcome measure (PROM) developed and validated in a large international cohort of patients, which identifies the patient reported toxicity and functional outcomes which impact HRQOL in SCCA.
The EORTC project aimed solely to evaluate the factors influencing HRQOL and did not evaluate patient (or HCP) views on survival or disease activity outcomes. By contrast, the present COS will serve as an overall framework to capture a wide range of agreed outcomes 
Strengths and limitations
The CORMAC study has a number of strengths. Our methodology is coherent with recommendations from an international consensus, 28 and was clearly defined a priori in a protocol. 17 Inclusion of both patients and HCPs at every stage ensured that outcomes in the final core set fairly represent their shared priorities. A unique strength of our consensus meeting, highlighted in the participant feedback, was directly bringing together patients and
HCPs, enabling each group to hear the others' views, facilitating open discussion. We ensured that the views of both stakeholder groups were represented equally, despite difference in the number of participants in each group, by applying the same consensus criteria to electronic voting as was used in the Delphi survey. Our comprehensive and rigorous longlisting process ensured that outcomes across all domains (survival, disease activity, life impact including HRQOL, toxicity and delivery of care) were considered during the consensus process.
There are some limitations to this study. Due to time and budgetary constraints, our project was conducted only in English. Despite this, our Delphi process included patient and HCP participants from 11 countries. The attrition rate for patient participants in the second round of our Delphi is slightly higher than in other recent COS projects, [29] [30] [31] possibly affected by the recruitment methods used. To maximise international reach, we disseminated Delphi invitations via social media and group e-mails through patient advocacy groups, with 62% of all patient participants being recruited via these channels. This group had the highest attrition rate, 33%, compared to 15% in those recruited via hospital sites, suggesting that participants recruited in this way are not as invested in the process as those recruited through personal contact.
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It is important to acknowledge the interplay between outcomes in the toxicity and life impact domains. The toxicity domain relates to physiological outcomes including symptoms, whereas the life impact domain relates to the functional items and composite measures of HRQOL. At the consensus meeting, both HCPs and patients described the functional impact of the included toxicity outcomes. However, patient participants also described the value of specific toxicity outcome data, for example, the incidence and duration of symptoms, in addition to measures of impact. Therefore, we feel that it is important to maintain the distinction between these two domains.
The life impact outcomes in the CORMAC COS include physical and sexual function as well as the composite measure of HRQOL. It is likely that the life impact and toxicity outcomes included in the CORMAC COS are factors in HRQOL in SCCA, but identifying the determinants of HRQOL was not the aim of this project and there are outcomes not included in the COS which influence HRQOL, as demonstrated by ANL-27. 27 The concordance between the toxicity and life impact outcomes included in the CORMAC COS and the question items included in ANL-27 makes it likely that ANL-27 will be recommended as the preferred measurement instrument for these core outcomes. However, definitive recommendations cannot be made until full evaluation of available instruments has been completed in next phase of the CORMAC project.
There were six outcomes that were not included in the final COS that at the consensus meeting were rated as critically important by patients, but not critically important by HCPs (Table 3) .
However, a COS is a minimum set of outcomes that should be included in trials in a particular field. The issues identified as of key importance to patients, including those not reaching the threshold for inclusion in the COS, can be used to aid the selection of additional outcomes of interest and to guide the research agenda going forward. A COS should also be reviewed periodically to determine whether any excluded outcomes should be added or any included outcomes removed. 12
Patient reported outcome Measures (PROMs) in Oncology
Toxicity outcome reporting in trials for SCCA interventions and in oncology in general has historically been poor, with toxicity outcomes frequently reported only in non-specific terms such as 'gastro-intestinal toxicity' or 'acute toxicity'. 15 The clinician-reported CTCAE (Common Terminology Criteria for Adverse Events) system is the most widely used tool for measuring toxicity in oncology trials 32 , including anal cancer trials 15 . However, there are no guidelines for the clinical application of a given toxicity grading system, such as methods of patient screening or data collection 33 and trial reports rarely describe these methods in any detail. 33 .
Clinician reporting of symptomatic toxicity outcomes has been shown to lack reliability 34 and under-estimate the incidence and severity of symptoms compared to patients' direct reports. [35] [36] [37] Recognition of these issues has led to the development of new instruments for direct patient reporting of toxicity outcomes, such as PRO-CTCAE 38 and eRAPID. 39 However, such patientreported outcomes measures do not necessarily include patient-important outcomes, and the issue of selecting which toxicity outcomes to measure in a given trial has yet to be adequately addressed. The eRAPID system has selected a number of outcomes frequently experienced during treatment for five of the most common cancers. Therefore, toxicities encountered during treatment for rare cancers, such as anal cancer, may not be represented. The PRO-CTCAE system is derived from the CTCAE and includes a comprehensive library of 124 symptomatic toxicity outcomes from which trialists can construct bespoke PROMs by selecting applicable question items. To-date, there are no recommended outcome subsets specific to SCCA. By identifying the toxicities of critical importance to patients and HCPs, the CORMAC COS will facilitate selection of health area-specific evaluation tools in future trials increasing relevance and reducing redundancy.
Future challenges and research
Efforts will be needed to promote and monitor uptake of this COS. The COMET Initiative works to promote COS utilisation, 40 and trial funding bodies, regulatory authorities and guideline development groups, such as the (UK) National Institute for Health Research, the European 
